Selected research
Industry Research
Sicca Syndrome Drug Industry Research Report 2026
Market perspective
The global Sicca Syndrome Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Sicca Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Sicca Syndrome Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Sicca Syndrome Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Sicca Syndrome Drug include Novartis AG, GlaxoSmithKline Plc, Biogen, Inc., Amgen Inc., UCB S.A., Toleranzia AB, Redx Pharma Plc, MedImmune, LLC and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Sicca Syndrome Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Sicca Syndrome Drug Market by Company
Novartis AG
GlaxoSmithKline Plc
Biogen, Inc.
Amgen Inc.
UCB S.A.
Toleranzia AB
Redx Pharma Plc
MedImmune, LLC
Bristol-Myers Squibb Company
Ampio Pharmaceuticals, Inc.
Akari Therapeutics, Plc
Sicca Syndrome Drug Segment by Type
BMS-986142
Coversin
Filgotinib
Belimumab
LY-3090106
Others
Sicca Syndrome Drug Segment by Application
Hospital
Clinic
Others
Sicca Syndrome Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sicca Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sicca Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sicca Syndrome Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Sicca Syndrome Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Sicca Syndrome Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Sicca Syndrome Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- BMS-986142
- Coversin
- Filgotinib
- Belimumab
- LY-3090106
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Novartis AG
- GlaxoSmithKline Plc
- Biogen, Inc.
- Amgen Inc.
- UCB S.A.
- Toleranzia AB
- Redx Pharma Plc
- MedImmune, LLC
- Bristol-Myers Squibb Company
- Ampio Pharmaceuticals, Inc.
- Akari Therapeutics, Plc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Sicca Syndrome Drug Market Size (2021-2032)
- 2.2.2 Global Sicca Syndrome Drug Sales (2021-2032)
- 2.2.3 Global Sicca Syndrome Drug Market Average Price (2021-2032)
- 2.3 Sicca Syndrome Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 BMS-986142
- 2.3.3 Coversin
- 2.3.4 Filgotinib
- 2.3.5 Belimumab
- 2.3.6 LY-3090106
- 2.3.7 Others
- 2.4 Sicca Syndrome Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Sicca Syndrome Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Sicca Syndrome Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Sicca Syndrome Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Sicca Syndrome Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Sicca Syndrome Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Sicca Syndrome Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Sicca Syndrome Drug, Product Type & Application
- 3.8 Global Manufacturers of Sicca Syndrome Drug, Established Date
- 3.9 Global Sicca Syndrome Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Sicca Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Sicca Syndrome Drug Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 GlaxoSmithKline Plc
- 4.2.1 GlaxoSmithKline Plc Company Information
- 4.2.2 GlaxoSmithKline Plc Business Overview
- 4.2.3 GlaxoSmithKline Plc Sicca Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GlaxoSmithKline Plc Sicca Syndrome Drug Product Portfolio
- 4.2.5 GlaxoSmithKline Plc Recent Developments
- 4.3 Biogen, Inc.
- 4.3.1 Biogen, Inc. Company Information
- 4.3.2 Biogen, Inc. Business Overview
- 4.3.3 Biogen, Inc. Sicca Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Biogen, Inc. Sicca Syndrome Drug Product Portfolio
- 4.3.5 Biogen, Inc. Recent Developments
- 4.4 Amgen Inc.
- 4.4.1 Amgen Inc. Company Information
- 4.4.2 Amgen Inc. Business Overview
- 4.4.3 Amgen Inc. Sicca Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Amgen Inc. Sicca Syndrome Drug Product Portfolio
- 4.4.5 Amgen Inc. Recent Developments
- 4.5 UCB S.A.
- 4.5.1 UCB S.A. Company Information
- 4.5.2 UCB S.A. Business Overview
- 4.5.3 UCB S.A. Sicca Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 UCB S.A. Sicca Syndrome Drug Product Portfolio
- 4.5.5 UCB S.A. Recent Developments
- 4.6 Toleranzia AB
- 4.6.1 Toleranzia AB Company Information
- 4.6.2 Toleranzia AB Business Overview
- 4.6.3 Toleranzia AB Sicca Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Toleranzia AB Sicca Syndrome Drug Product Portfolio
- 4.6.5 Toleranzia AB Recent Developments
- 4.7 Redx Pharma Plc
- 4.7.1 Redx Pharma Plc Company Information
- 4.7.2 Redx Pharma Plc Business Overview
- 4.7.3 Redx Pharma Plc Sicca Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Redx Pharma Plc Sicca Syndrome Drug Product Portfolio
- 4.7.5 Redx Pharma Plc Recent Developments
- 4.8 MedImmune, LLC
- 4.8.1 MedImmune, LLC Company Information
- 4.8.2 MedImmune, LLC Business Overview
- 4.8.3 MedImmune, LLC Sicca Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 MedImmune, LLC Sicca Syndrome Drug Product Portfolio
- 4.8.5 MedImmune, LLC Recent Developments
- 4.9 Bristol-Myers Squibb Company
- 4.9.1 Bristol-Myers Squibb Company Company Information
- 4.9.2 Bristol-Myers Squibb Company Business Overview
- 4.9.3 Bristol-Myers Squibb Company Sicca Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Bristol-Myers Squibb Company Sicca Syndrome Drug Product Portfolio
- 4.9.5 Bristol-Myers Squibb Company Recent Developments
- 4.10 Ampio Pharmaceuticals, Inc.
- 4.10.1 Ampio Pharmaceuticals, Inc. Company Information
- 4.10.2 Ampio Pharmaceuticals, Inc. Business Overview
- 4.10.3 Ampio Pharmaceuticals, Inc. Sicca Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Ampio Pharmaceuticals, Inc. Sicca Syndrome Drug Product Portfolio
- 4.10.5 Ampio Pharmaceuticals, Inc. Recent Developments
- 4.11 Akari Therapeutics, Plc
- 4.11.1 Akari Therapeutics, Plc Company Information
- 4.11.2 Akari Therapeutics, Plc Business Overview
- 4.11.3 Akari Therapeutics, Plc Sicca Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Akari Therapeutics, Plc Sicca Syndrome Drug Product Portfolio
- 4.11.5 Akari Therapeutics, Plc Recent Developments
5 Global Sicca Syndrome Drug Market Scenario by Region
- 5.1 Global Sicca Syndrome Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Sicca Syndrome Drug Sales by Region: 2021-2032
- 5.2.1 Global Sicca Syndrome Drug Sales by Region: 2021-2026
- 5.2.2 Global Sicca Syndrome Drug Sales by Region: 2027-2032
- 5.3 Global Sicca Syndrome Drug Revenue by Region: 2021-2032
- 5.3.1 Global Sicca Syndrome Drug Revenue by Region: 2021-2026
- 5.3.2 Global Sicca Syndrome Drug Revenue by Region: 2027-2032
- 5.4 North America Sicca Syndrome Drug Market Facts & Figures by Country
- 5.4.1 North America Sicca Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Sicca Syndrome Drug Sales by Country (2021-2032)
- 5.4.3 North America Sicca Syndrome Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Sicca Syndrome Drug Market Facts & Figures by Country
- 5.5.1 Europe Sicca Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Sicca Syndrome Drug Sales by Country (2021-2032)
- 5.5.3 Europe Sicca Syndrome Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Sicca Syndrome Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Sicca Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Sicca Syndrome Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Sicca Syndrome Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Sicca Syndrome Drug Market Facts & Figures by Country
- 5.7.1 South America Sicca Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Sicca Syndrome Drug Sales by Country (2021-2032)
- 5.7.3 South America Sicca Syndrome Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Sicca Syndrome Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Sicca Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Sicca Syndrome Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Sicca Syndrome Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Sicca Syndrome Drug Sales by Type (2021-2032)
- 6.1.1 Global Sicca Syndrome Drug Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Sicca Syndrome Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Sicca Syndrome Drug Revenue by Type (2021-2032)
- 6.2.1 Global Sicca Syndrome Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Sicca Syndrome Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Sicca Syndrome Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Sicca Syndrome Drug Sales by Application (2021-2032)
- 7.1.1 Global Sicca Syndrome Drug Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Sicca Syndrome Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Sicca Syndrome Drug Revenue by Application (2021-2032)
- 7.2.1 Global Sicca Syndrome Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Sicca Syndrome Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Sicca Syndrome Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Sicca Syndrome Drug Value Chain Analysis
- 8.1.1 Sicca Syndrome Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Sicca Syndrome Drug Production Mode & Process
- 8.2 Sicca Syndrome Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Sicca Syndrome Drug Distributors
- 8.2.3 Sicca Syndrome Drug Customers
9 Global Sicca Syndrome Drug Analyzing Market Dynamics
- 9.1 Sicca Syndrome Drug Industry Trends
- 9.2 Sicca Syndrome Drug Industry Drivers
- 9.3 Sicca Syndrome Drug Industry Opportunities and Challenges
- 9.4 Sicca Syndrome Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst